Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis.
<h4>Aim</h4>The benefit of nucleot(s)ide analogues (NA) for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative treatment has been widely debated due to the relatively weak evidence. The objective of this systematic review was to evaluate the effect of NA on rec...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0102761 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850076481134264320 |
|---|---|
| author | Ping Sun Xiaochuan Dong Xiang Cheng Qinggang Hu Qichang Zheng |
| author_facet | Ping Sun Xiaochuan Dong Xiang Cheng Qinggang Hu Qichang Zheng |
| author_sort | Ping Sun |
| collection | DOAJ |
| description | <h4>Aim</h4>The benefit of nucleot(s)ide analogues (NA) for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative treatment has been widely debated due to the relatively weak evidence. The objective of this systematic review was to evaluate the effect of NA on recurrence and survival after curative treatment of HBV-HCC.<h4>Methods</h4>A systematic electronic search was performed. All controlled trials comparing NA versus placebo or no treatment were considered for inclusion. Results were expressed as Hazard Ratio for recurrence and survival with 95% confidence intervals using RevMan 5.2.<h4>Results</h4>We included 13 trials with 6350 patients. There were significant improvements for recurrence-free survival (HR 0.66, 95% CI 0.54-0.80; p<0.0001) and overall survival (HR 0.56, 95% CI 0.43-0.73; p<0.0001) in the adjuvant NA group compared with the control group. Sensitivity analyses confirmed the robustness of the results. There were no serious adverse effects being reported. Lamivudine resistance was from 28.6% to 37.5% but could be rescued by other types of NA or combination therapy.<h4>Conclusion</h4>Our study suggested benefits of adjuvant NA therapy following curative treatment of HBV-HCC. Since the great proven efficacy of NA in improving clinical and viral parameters besides HCC, further studies should be focused on broadening the indications for NA therapy after curative treatment of HBV-HCC. |
| format | Article |
| id | doaj-art-58833f0479f044cc8c3e801467286e1c |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-58833f0479f044cc8c3e801467286e1c2025-08-20T02:46:01ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0197e10276110.1371/journal.pone.0102761Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis.Ping SunXiaochuan DongXiang ChengQinggang HuQichang Zheng<h4>Aim</h4>The benefit of nucleot(s)ide analogues (NA) for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative treatment has been widely debated due to the relatively weak evidence. The objective of this systematic review was to evaluate the effect of NA on recurrence and survival after curative treatment of HBV-HCC.<h4>Methods</h4>A systematic electronic search was performed. All controlled trials comparing NA versus placebo or no treatment were considered for inclusion. Results were expressed as Hazard Ratio for recurrence and survival with 95% confidence intervals using RevMan 5.2.<h4>Results</h4>We included 13 trials with 6350 patients. There were significant improvements for recurrence-free survival (HR 0.66, 95% CI 0.54-0.80; p<0.0001) and overall survival (HR 0.56, 95% CI 0.43-0.73; p<0.0001) in the adjuvant NA group compared with the control group. Sensitivity analyses confirmed the robustness of the results. There were no serious adverse effects being reported. Lamivudine resistance was from 28.6% to 37.5% but could be rescued by other types of NA or combination therapy.<h4>Conclusion</h4>Our study suggested benefits of adjuvant NA therapy following curative treatment of HBV-HCC. Since the great proven efficacy of NA in improving clinical and viral parameters besides HCC, further studies should be focused on broadening the indications for NA therapy after curative treatment of HBV-HCC.https://doi.org/10.1371/journal.pone.0102761 |
| spellingShingle | Ping Sun Xiaochuan Dong Xiang Cheng Qinggang Hu Qichang Zheng Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PLoS ONE |
| title | Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. |
| title_full | Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. |
| title_fullStr | Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. |
| title_full_unstemmed | Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. |
| title_short | Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. |
| title_sort | nucleot s ide analogues for hepatitis b virus related hepatocellular carcinoma after curative treatment a systematic review and meta analysis |
| url | https://doi.org/10.1371/journal.pone.0102761 |
| work_keys_str_mv | AT pingsun nucleotsideanaloguesforhepatitisbvirusrelatedhepatocellularcarcinomaaftercurativetreatmentasystematicreviewandmetaanalysis AT xiaochuandong nucleotsideanaloguesforhepatitisbvirusrelatedhepatocellularcarcinomaaftercurativetreatmentasystematicreviewandmetaanalysis AT xiangcheng nucleotsideanaloguesforhepatitisbvirusrelatedhepatocellularcarcinomaaftercurativetreatmentasystematicreviewandmetaanalysis AT qingganghu nucleotsideanaloguesforhepatitisbvirusrelatedhepatocellularcarcinomaaftercurativetreatmentasystematicreviewandmetaanalysis AT qichangzheng nucleotsideanaloguesforhepatitisbvirusrelatedhepatocellularcarcinomaaftercurativetreatmentasystematicreviewandmetaanalysis |